Investigation of Potential Pharmacodynamic and Pharmacokinetic Interactions Between Selexipag and Warfarin in Healthy Male Subjects

Bruderer, Shirin; Okubo, Kaori; Mukai, Hideya; Mant, Tim; Dingemanse, Jasper

doi:10.1016/j.clinthera.2016.03.014

Cited by 21 publications

(15 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is not expected that selexipag and MRE-269 affect the PK of other drugs through CYP enzymes or drug transporters, and they both showed no impact on the pharmacokinetics or pharmacodynamics of warfarin. 23 There were no clinically relevant issues in patients treated with the combined use of selexipag with an ERA and a PDE-5 inhibitor. In our study, tolerance of selexipag was similar among Japanese patients who received any dose within the selexipag regimen.…”

Section: Acknowledgmentsmentioning

confidence: 93%

Efficacy and Safety of an Orally Administered Selective Prostacyclin Receptor Agonist, Selexipag, in Japanese Patients With Pulmonary Arterial Hypertension

Tanabe

Ikeda

Tahara

et al. 2017

Circ J

View full text Add to dashboard Cite

show abstract

Section: Acknowledgmentsmentioning

confidence: 93%

Efficacy and Safety of an Orally Administered Selective Prostacyclin Receptor Agonist, Selexipag, in Japanese Patients With Pulmonary Arterial Hypertension

Tanabe

Ikeda

Tahara

et al. 2017

Circ J

View full text Add to dashboard Cite

show abstract

“…46 PAH hastalarında sıklıkla kullanılan varfarin ile birlikte alınması durumunda ilaç etkileşimi olmadığı bildirilmektedir. 47 Benzer şekilde, fosfodiesteraz-5 inhibitörleri ve endotelin reseptör antagonistleri ile de ilaç etkileşimi saptanmamıştır. Yarılanma ömrü 9-12 saat olup günde 2 kez kullanılmaktadır.…”

Section: Seleksi̇pagunclassified

Prostacyclin Analogues and Prostacyclin Receptors Agonists in Pulmonary Arterial Hypertension: Review

Çörtük¹,

Çetınkaya²

2017

Turkiye Klinikleri Arch Lung

View full text Add to dashboard Cite

ulmoner hipertansiyon (PH) pulmoner arterde artmış basıncı ifade etmektedir. Tek başına pulmoner arterde basınç artışı olduğunda gelişen PH; pulmoner arteriyel hipertansiyon (PAH) olarak, pulmoner venöz ve kapiller sistemdeki değişikliklere sekonder gelişen PH ise pulmoner venöz hipertansiyon olarak adlandırılır. PAH, pulmoner vasküler rezistans (PVR)'ın ilerleyici artışı, pulmoner vasküler kompliyansın azalması ve artan pulmoner arter basıncı (PAB) sonucu ortaya çıkan sağ kalp disfonksiyonu ve ölüme neden olan prognozu kötü bir hastalıktır. A An na ah h t ta ar r K Ke e l li i m me e l le er r: : Reseptörler, prostaglandin; hipertansiyon, pulmoner; ilaç tedavisi A AB BS S T TR RA AC CT T Pulmonary hypertension (PH) is a group of disease. It is made up of 5 groups according to World Health Organization classification and Group 1 is named as pulmonary arterial hypertension (PAH). PAH can be idiopathic, as well it can be due to gene mutations, drugs toxins, connective tissue diseases, portal hypertension and etc. Prostacyclin plays an important role in the PAH pathophysiology. Prostacyclin is a prostaglandin derived from arachidonic acid in the endothelium. It causes vasodilation, and has anti-inflammatory, anti-thrombotic and anti-proliferative effects. Based on the determination of importance of prostacyclins in the PAH pathophysiology, Prostacyclin analogous and very recently prostaglandin receptor agonists have been developed. The aim of this review is to present current literature information about prostacyclin analogues and prostaglandin receptor agonists used in the PAH treatment.K Ke ey y W Wo or rd ds s: : Receptors, prostaglandin; hypertension, pulmonary; drug therapy T Tu ur rk ki iy ye e K Kl li in ni ik kl le er ri i A Ar rc ch h L Lu un ng g 2 20 01 17 7; ;1 18 8( (1 1) ): :1 17 7--2 24 4

show abstract

“…Because warfarin is routinely prescribed as a mode of anticoagulation for patients with PAH, a recently published phase 1 study looked at the potential pharmacodynamic and PK interactions between selexipag and warfarin. 50 In this double-blind, 2-way, 2-treatment crossover study, 19 healthy men were recruited. They were administered a single dose of selexipag 400 μg or placebo on day 1, followed by twice-daily doses of selexipag or placebo on days 2 through 12.…”

Section: Newer Drugs In Pahmentioning

confidence: 99%

Selexipag in Pulmonary Arterial Hypertension: Most Updated Evidence From Recent Preclinical and Clinical Studies

Ghosh

Ball

Das

et al. 2016

The Journal of Clinical Pharma

View full text Add to dashboard Cite

Pulmonary arterial hypertension (PAH) is a relatively rare disease that, due to its chronic nature, has always been difficult to treat effectively. Selexipag is an oral prostacyclin (PGI ) agonist that was approved by US Food and Drug Administration (US FDA) in December 2015 for the treatment of PAH. After its success in phase 1 and phase 2 clinical trials regarding the convenient oral twice-daily dosing and low side-effect profile, selexipag raised the hope of controlling the disease progression in PAH patients. In the recently completed multicentered phase 3 study (GRIPHON), selexipag has been shown to reduce death and hospitalization due to PAH significantly, an effect that was consistent across different ranges of maintenance dose. In the same study selexipag use was also associated with an increase in 6-minute walk distance (a measure of symptom severity) from baseline, but no significant improvement in all-cause mortality could be observed. The results of the ongoing phase 3 studies (TRITON and TRANSIT-1) are expected to throw some more light on the safety and efficacy of this novel molecule across various treatment scenarios. Hence, our article aims to summarize all the available information from preclinical and clinical studies published to date on the pharmacodynamics, pharmacokinetics, efficacy, safety (in general and in scenarios such as hepatic and renal function impairment), significant drug interactions (with warfarin and antiretroviral drugs), and clinical significance of oral selexipag in patients with PAH.

show abstract

Investigation of Potential Pharmacodynamic and Pharmacokinetic Interactions Between Selexipag and Warfarin in Healthy Male Subjects

Cited by 21 publications

References 25 publications

Efficacy and Safety of an Orally Administered Selective Prostacyclin Receptor Agonist, Selexipag, in Japanese Patients With Pulmonary Arterial Hypertension

Efficacy and Safety of an Orally Administered Selective Prostacyclin Receptor Agonist, Selexipag, in Japanese Patients With Pulmonary Arterial Hypertension

Prostacyclin Analogues and Prostacyclin Receptors Agonists in Pulmonary Arterial Hypertension: Review

Selexipag in Pulmonary Arterial Hypertension: Most Updated Evidence From Recent Preclinical and Clinical Studies

Contact Info

Product

Resources

About